The United States of America As Represented by the Department of Health

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

The United States of America As Represented by the Secretary of

Celgene Corporation

Genetics Institute, Inc.

Robert Yarchoan

Samuel Broder

Giovanna Tosato

Hiroaki Mitsuya

Matthew L Sherman

Gene M Shearer

Richard S Little

James M Pluda

Ellen Feigal

Kathleen Wyvill

Jill Lietzau

Jerome B Zeldis

Jay A Berzofsky

Warren Jaye Leonard

Vikram Khetani

Takahiro Okazaki

Warner C Greene

David A Nelson

Irini Sereti

Thomas S Uldrick

Andrew Catanzaro

Denise Whitby

David A Davis

Mark N Polizzotto

James T Snyder, Ii

M Wayne Saville

Kazuyuki Taga

Laurence Rubin

William Biddison

David Davis

Mark Polizzotto

Provided herein are uses of gene and protein biomarkers as a predictor of clinical sensitivity of Kaposi's sarcoma (KS) or Kaposi's sarcoma-associated herpesvirus (KSHV) induced lymphoma and patient response to treatment with an immunomodulatory compound. Further provided herein are methods for the treatment or management of Kaposi's sarcoma or KSHV-induced lymphoma with an immunomodulatory compound, alone or in combination with doxorubicin.

Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus

Methods are provided for using IL-12 to treat Kaposi's sarcoma (KS), particularly AIDS-associated KS.

Treatment of Kaposi's sarcoma with IL-12

The present invention provides a method of inhibiting the replication of human immunodeficiency virus in cells which are infected with HIV comprising administering to the cells a replication inhibiting amount of interleukin-10. Also provided is a parenteral method of the administration of interleukin-10 administration. Further provided is a method of inhibiting retroviral replication in a human subject infected by a retrovirus, comprising administering to the subject an inhibiting amount of interleukin-10, including the retrovirus is. Finally, a method of treating Kaposi's sarcoma in a human subject comprising administering to the subject an effective amount of interleukin-10 to the subject is provided.

Methods of inhibiting viral replication using IL-10

A method for inhibiting intracellular replication of HIV in an HIV-infected individual comprising contacting the HIV reverse transcriptase in the HIV-infected cells with 2',3'-dideoxyadenosine-5'-triphosphate whose source is 2',3'-dideoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof.

Method of inhibiting HIV replication with 2',3'-dideoxyadenosine

A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.

Treatment of retroviral induced dementia by administration of

A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.

Treatment of human retroviral infections with 2',3'-dideoxyinosine alone

The present invention discloses a sandwich method and a kit for assaying interleukin-2 receptor (IL-2R) in a sample. The method comprises determining reactivity of said sample with a plurality of ligands, each said ligand having binding affinity for a specific site on the receptor, said site being different for each said ligand and distinct from interleukin-2 binding site on the receptor. The invention also discloses a method of detecting such disturbed or abnormal conditions in humans which release soluble IL-2R in the body fluid.

Soluble interleukin-2 receptor as a disease indicator and a method of

Growing community of inventors

Bethesda, MD, United States of America

Robert Yarchoan